Authors
Professor of medicine at Robert Wood Johnson Medical School & medical oncologist at Rutgers Cancer Institute.
Direct of the Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center
Avi Mamidi, PharmD, RPh, is the director of North America Market Access at ResMed.
Advertisement
Advertisement
Trending on AJMC
1
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
4
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
5




